BioLife Solutions, Inc. $BLFS Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. increased its position in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 2.4% in the third quarter, HoldingsChannel.com reports. The firm owned 2,967,518 shares of the medical equipment provider’s stock after acquiring an additional 70,248 shares during the quarter. Vanguard Group Inc. owned about 0.06% of BioLife Solutions worth $75,701,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the business. Forum Private Client Group LLC purchased a new stake in BioLife Solutions during the 2nd quarter worth about $232,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of BioLife Solutions during the 2nd quarter worth about $205,000. Geode Capital Management LLC increased its holdings in shares of BioLife Solutions by 3.8% in the 2nd quarter. Geode Capital Management LLC now owns 921,105 shares of the medical equipment provider’s stock valued at $19,842,000 after acquiring an additional 33,849 shares during the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in shares of BioLife Solutions in the 2nd quarter valued at about $286,000. Finally, Stephens Investment Management Group LLC raised its position in shares of BioLife Solutions by 14.5% during the 3rd quarter. Stephens Investment Management Group LLC now owns 608,814 shares of the medical equipment provider’s stock worth $15,531,000 after acquiring an additional 77,095 shares in the last quarter. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on BLFS shares. Wall Street Zen upgraded BioLife Solutions from a “hold” rating to a “buy” rating in a research note on Saturday, February 28th. HC Wainwright reissued a “buy” rating and set a $32.00 price objective on shares of BioLife Solutions in a report on Monday, December 29th. Zacks Research upgraded shares of BioLife Solutions from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 23rd. UBS Group restated a “buy” rating on shares of BioLife Solutions in a report on Monday, December 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Insider Buying and Selling at BioLife Solutions

In other BioLife Solutions news, Director Amy Duross sold 2,000 shares of BioLife Solutions stock in a transaction on Monday, December 15th. The shares were sold at an average price of $24.60, for a total value of $49,200.00. Following the transaction, the director directly owned 18,687 shares in the company, valued at approximately $459,700.20. The trade was a 9.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Troy Wichterman sold 990 shares of BioLife Solutions stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $25.59, for a total transaction of $25,334.10. Following the completion of the transaction, the chief financial officer owned 150,746 shares in the company, valued at approximately $3,857,590.14. This represents a 0.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 10,020 shares of company stock valued at $241,593. 2.20% of the stock is owned by insiders.

Key BioLife Solutions News

Here are the key news stories impacting BioLife Solutions this week:

• Positive Sentiment: Analyst/preview: Seeking Alpha highlights BioLife’s strategic refocus on core biopreservation media and vials, forecasting ~17–20% revenue growth in FY2026, positive GAAP net income and mid‑60s gross margins; cites the PanTHERA acquisition and a QKine partnership as drivers of higher ARPU and next‑gen product launches by late‑2026. BioLife Looks Strong For Fiscal Year 2026
• Positive Sentiment: Company presentation/press release: BioLife reiterated its growth and strategic refocus in a recent presentation, reinforcing management’s turnaround narrative and the FY26 outlook that underpins the Seeking Alpha preview. BioLife Solutions Highlights Growth and Strategic Refocus in Presentation
• Neutral Sentiment: Short‑interest data published for early March shows zero shares / 0.0 days‑to‑cover — this appears erroneous or non‑informative and does not indicate material short pressure at present. MarketBeat BLFS
• Negative Sentiment: Insider selling: Multiple senior executives (CFO, CMO, EVP, CTO and others) disclosed modest open‑market sales (hundreds of shares apiece at ≈$20.74). Amounts are small relative to their holdings, but clustered sales can trigger short‑term headline risk and investor caution. Insider trading alert

BioLife Solutions Trading Down 1.3%

BLFS stock opened at $19.86 on Friday. The company has a market capitalization of $959.24 million, a P/E ratio of -180.53 and a beta of 1.90. The business has a 50 day simple moving average of $23.37 and a 200-day simple moving average of $25.07. BioLife Solutions, Inc. has a twelve month low of $19.10 and a twelve month high of $29.62.

About BioLife Solutions

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.